Psoriasis Vulgaris
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Psoriasis Vulgaris is a moderately active landscape with 76 programs across 30 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Revance Therapeutics, Inc., Bristol-Myers Squibb. 20 therapies are approved with 8 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
81%
Small molecule
87 of 107 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 107 classified programs, each share of the total. Modality classified for 100% of 108 pipeline programs.
Analysis
Trial Status
81
clinical trials
Clinical Trials
Trial Activity
81 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)